Degenerate expression of transcription coregulator
proteins is observed in most human
cancers. Therefore, in targeted anti-
cancer therapy development, intervention at the level of
cancer-specific transcription is of high interest. The
steroid receptor coactivator-1 (SRC-1) is highly expressed in breast, endometrial, and
prostate cancer. It is present in various transcription complexes, including those containing
nuclear hormone receptors. We examined the effects of a
peptide that contains the LXXLL-motif of the human SRC-1
nuclear receptor box 1 linked to the cell-penetrating
transportan 10 (TP10), hereafter referred to as TP10-SRC1LXXLL, on proliferation and
estrogen-mediated transcription of
breast cancer cells in vitro. Our data show that TP10-SRC1LXXLL induced dose-dependent cell death of
breast cancer cells, and that this effect was not affected by
estrogen receptor (ER) status. Surprisingly TP10-SRC1LXXLL severely reduced the viability and proliferation of
hormone-unresponsive
breast cancer MDA-MB-231 cells. In addition, the regulation of the endogenous ERĪ± direct target gene pS2 was not affected by TP10-SRC1LXXLL in
estrogen-stimulated MCF-7 cells. Dermal fibroblasts were similarly affected by treatment with higher concentrations of TP10-SRC1LXXLL and this effect was significantly delayed. These results suggest that the TP10-SRC1LXXLL
peptide may be an effective
drug candidate in the treatment of
cancers with minimal therapeutic options, for example ER-negative
tumors.